610O Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6

Manish Patel, E.P. Hamilton, Sarina A. Piha‐Paul, J. Henry, Udai Banerji, Mohammed Najeeb Al Hallak, Hitoshi Okada, M. Qian, X. Zhang, Nur Akmarina B.M. Said, V. Chatikhine, E. Fontana